Director · Lexeo Therapeutics, Inc. · Lexeo Therapeutics, Inc. — Stock Option (right to buy)
Side
A
Value
—
Shares
35.0K
Price
—
Executed
Jun 25, 2026
Disclosed
Jun 29, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 25 executedJun 29, 2026 disclosed
LXEO · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Lexeo Therapeutics, Inc. — Stock Option (right to buy)
Ticker
LXEO
Shares
35.0K
Price per share
$0
Execution date (reported)
Jun 25, 2026
Owned after transaction
35.0K shares
Days from execution to publication
4
What this establishes
Agger Mette Kirstine filed this Form 4 reporting a grant or award of LXEO on Jun 25, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Agger Mette Kirstinecik:0001722234
Issuer
Lexeo Therapeutics, Inc.cik:0001907108
Revision history · 0
No field has changed since this record was first ingested.
